<DOC>
	<DOC>NCT02600819</DOC>
	<brief_summary>This study will evaluate the safety and tolerability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) in HIV-1 infected adults with end stage renal disease (ESRD) on chronic hemodialysis (HD) at Week 48.</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis</brief_title>
	<detailed_description />
	<criteria>Key Currently on a stable antiretroviral regimen for ≥ 6 consecutive months Plasma HIV1 RNA concentrations &lt; 50 copies/mL for ≥ 6 months preceding the screening visit and have HIV1 RNA &lt; 50 copies/mL at screening No documented history of HIV1 resistance to EVG, FTC, lamivudine (3TC) or TFV and no history of switching off EVG, FTC, 3TC or TFV due to concern for resistance CD4+ T cell count ≥ 200 cells/μL ESRD with estimated glomerular filtration rate (eGFR) &lt; 15 mL/min by CockcroftGault formula for creatinine clearance On chronic HD for ≥ 6 months prior to screening Adequate hematologic function (absolute neutrophil count ≥ 1,000/mm^3; platelets ≥ 50,000/mm^3; hemoglobin ≥ 8.5 g/dL) Key Hepatitis B coinfection Any clinical history, condition, or test result that, in the opinion of the Investigator, would make the individual unsuitable for the study or unable to comply with dosing requirements Administration of other investigational agents (unless approved by Gilead Sciences). Participation in any other clinical trial, including observational trials, without prior approval from the sponsor is prohibited while participating in this trial. History or presence of allergy or intolerance to the study drugs or their components A new AIDSdefining condition (excluding CD4+ T cell count and percentage criteria) diagnosed within the 30 days prior to screening, with the exception of oropharyngeal candidiasis Received solid organ or bone marrow transplant Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>end stage renal disease (ESRD)</keyword>
	<keyword>hemodialysis (HD)</keyword>
	<keyword>open-label</keyword>
	<keyword>HIV-1 Infection</keyword>
</DOC>